Last reviewed 2026-05-16 · How we verify

Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

Meningococcal ACYW135 Polysaccharide Conjugate Vaccine is a Polysaccharide conjugate vaccine Biologic drug developed by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. It is currently in Phase 3 development for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Also known as: Menwaycon.

This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135 by presenting conjugated polysaccharide antigens.

This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135 by presenting conjugated polysaccharide antigens. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.

At a glance

Mechanism of action

The vaccine uses polysaccharide capsules from four meningococcal serogroups conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these serogroups.

Approved indications

• Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135

Common side effects

• Injection site pain/erythema
• Fever
• Myalgia
• Headache

Key clinical trials

• Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (PHASE4)
• Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants (PHASE4)
• A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds (PHASE3)
• A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds (PHASE3)
• A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population (PHASE3)
• A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (PHASE3)
• Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months (PHASE3)
• Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Meningococcal ACYW135 Polysaccharide Conjugate Vaccine CI brief — competitive landscape report
• Meningococcal ACYW135 Polysaccharide Conjugate Vaccine updates RSS · CI watch RSS
• Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd portfolio CI

Frequently asked questions about Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

Related

• Drug class: All Polysaccharide conjugate vaccine drugs
• Target: All drugs targeting Meningococcal serogroup A, C, Y, and W-135 polysaccharide capsules
• Manufacturer: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — full pipeline
• Therapeutic area: All drugs in Immunology / Infectious Disease
• Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135
• Also known as: Menwaycon
• Compare: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine vs similar drugs
• Pricing: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine cost, discount & access